Follow the news, literature, and elearning on new developments in the management of Heart Failure.
AHA 2018 Little was known about the safety of sacubitril-valsartan in acute heart failure. PIONEER-HF addressed this question and found use of the ARNI to be safe and to lower NT-proBNP.
AHA 2018 The pilot TRED-HF study evaluated a phased withdrawal of HF therapy in patients who responded well to therapy and found that this likely reflects remission rather than full recovery.
AHA 2018 The TRED-HF evaluated well monitored withdrawal of pharmacological HF therapy and found that about 40% of patients deemed to have recovered DCM showed relapse.
AHA 2018 The results of the PIONEER-HF trial support the in-hospital initiation of sacubitril/valsartan in stabilized patients with acute decompensated heart failure and reduced EF.
AHA 2018 Dapagliflozin was associated with a reduction in CVD/hospitalization in T2DM patients with ASCVD or with multiple risk factors, and with a modest decrease in MACE in those with existing ASCVD.
The real-world EMPRISE trial showed reduced risk for HF hospitalization with the SGLT2 inhibitor empagliflozin, compared with DPP-4 inhibitors in subjects with T2DM and CVD.
HFpEF: The essentials to know There are several diagnostic approaches for HFpEF. Dr. Borlaug discusses their usefulness and limitations.
In patients with heart failure, compared with sinus rhythm, atrial fibrillation was associated with worse long-term cardiovascular outcomes in HFmrEF and HFpEF, but not in chronic or acute HFrEF.
HFpEF: The essentials to know Prof. Adriaan Voors gives a general overview on the history, epidemiology and prognosis of HFpEF
Despite specific recommendations on its management in the 2016 ESC Heart Failure Guidelines, iron deficiency is insufficiently diagnosed and treated in clinical practice. Practical guidance is now provided to complement the ESC Guidelines.
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.
CME accredited course focussed on the management of patients with heart failure and diabetes. Member registration (free) is needed to enroll in this course